Table 5.
TNFRSF1A genotype distribution according to patients’ radiation-induced skin reactions severity after subsequent cycles of RTH
| RTH week | Radiation reaction grade | TT (n = 5; 8.6%) | GG (n = 22; 37.9%) | GT (n = 31; 53.5%) | p |
|---|---|---|---|---|---|
| 1 | 0 (n = 6; 10.3%) | 1 (16.7%) | 3 (50%) | 2 (33.3%) | 0.905 |
| 1 (n = 52; 89.7%) | 4 (7.7%) | 19 (36.5%) | 29 (55.8%) | ||
| 2 | 1 (n = 34; 58.6%) | 5 (14.7%) | 13 (38.2%) | 16 (47.1%) | 0.297 |
| 2 (n = 24; 41.4%) | 0 | 9 (37.5%) | 15 (62.5%) | ||
| 3 | 1 (n = 20; 34.5%) | 2 (10%) | 9 (45%) | 9 (45%) | 0.813 |
| 2 and 3 (n = 38; 65.5%) | 3 (7.9%) | 13 (34.2%) | 22 (57.9%) | ||
| 1 and 2 (n = 54; 93.1%) | 5 (9.3%) | 20 (37%) | 29 (53.7%) | 0.932 | |
| 3 (n = 4; 6.9%) | 0 | 2 (50%) | 2 (50%) | ||
| 4 | 1 (n = 11; 19%) | 1 (9.1%) | 6 (54.5%) | 4 (36.4%) | 0.554 |
| 2 and 3 (n = 47; 81%) | 4 (8.5%) | 16 (34%) | 27 (57.4%) | ||
| 1 and 2 (n = 47; 81%) | 4 (8.5%) | 20 (42.6%) | 23 (48.9%) | 0.440 | |
| 3 (n = 11; 19%) | 1 (9.1%) | 2 (18.2%) | 8 (72.7%) | ||
| 5 | 1 (n = 6; 10.3%) | 0 | 4 (66.7%) | 2 (33.3%) | 0.635 |
| 2 and 3 (n = 52; 89.7%) | 5 (9.6%) | 18 (34.6%) | 29 (55.8%) | ||
| 1 and 2 (n = 46; 79.3%) | 3 (6.5%) | 21 (45.7%) | 22 (47.8%) | 0.157 | |
| 3 (n = 12; 20.7%) | 2 (16.7%) | 1 (8.3%) | 9 (75%) | ||
| 6 | 1 (n = 6; 10.3%) | 0 | 4 (66.7%) | 2 (33.3%) | 0.635 |
| 2 and 3 (n = 52; 89.7%) | 5 (9.6%) | 18 (34.6%) | 29 (55.8%) | ||
| 1 and 2 (n = 45; 77.6%) | 3 (6.6%) | 21 (46.7%) | 21 (46.7%) | 0.108 | |
| 3 (n = 13; 22.4%) | 2 (15.4%) | 1 (7.7%) | 10 (76.9%) | ||
| 7 | 1 (n = 5; 8.6%) | 0 | 3 (60%) | 2 (40%) | 0.890 |
| 2 and 3 (n = 53; 91.4%) | 5 (9.4%) | 19 (35.8%) | 29 (54.7%) | ||
| 1 and 2 (n = 34; 58.6%) | 1 (2.9%) | 18 (52.9%) | 15 (44.1%) | 0.037 | |
| 3 (n = 24; 41.4%) | 4 (16.7%) | 4 (16.7%) | 16 (66.6%) |